Anticancer Effects of the Novel Pyrazolyl-Urea GeGe-3

Area of Science:

• Medicinal Chemistry
• Cancer Biology
• Pharmacology

Background:

• Novel pyrazole compounds are being investigated for therapeutic applications.
• Angiogenesis plays a critical role in tumor growth and metastasis.
• Targeting protein kinases and calcium-binding proteins are strategies in cancer therapy.

Purpose of the Study:

• To identify and characterize novel anticancer compounds from a pyrazole library.
• To evaluate the anti-angiogenic and anti-proliferative effects of a lead compound, GeGe-3.
• To explore the potential of GeGe-3 in various human cancer cell lines.

Main Methods:

• Screening of over 200 novel pyrazole compounds.
• In vitro assays to assess anti-angiogenic properties, cell proliferation, metabolism, and migration.
• Testing on multiple established cancer cell lines (PC3, SKMEL-28, SKOV-3, Hep-G2, MDA-MB231, SKBR3, MCF7, A549, HeLa).

Main Results:

• Ethyl 1-(2-hydroxypentyl)-5-(3-(3-(trifluoromethyl)phenyl)ureido)-1H-pyrazole-4-carboxylate (GeGe-3) identified as a potent anticancer agent.
• GeGe-3 demonstrated significant anti-angiogenic properties, potentially by targeting DMPK1 and calreticulin.
• GeGe-3 inhibited proliferation and metabolism in cancer cell lines at 10 μM and reduced PC3 cell migration.

Conclusions:

• GeGe-3 exhibits significant anticancer potential, including anti-angiogenic and anti-proliferative effects.
• The compound warrants further preclinical investigation to elucidate its molecular targets and mechanisms of action.
• GeGe-3 represents a promising candidate for the development of new cancer therapeutics.